No abstract

The new heterocyclic compounds are used to treat epilepsy. In the present work new indole derivatives i.e. 5-[2(3)-di alkyl amino alkoxy] Indole 2,3-di-one derivatives are synthesized and characterized and these compounds was subjected to acute toxicity and then screened for antiepileptic activity on Maximal Electroshock (MES) seizures model in albino wistar rats. In that study 5-[2-dimethyl amino ethoxy] Indole 2,3 dione and 5-[2-dimethyl amino ethoxy] Indole 2-one,3-semicarbazone(IVa) showed good antiepileptic activity and less neurotoxicity compared to phenytoin. The purpose of the present study is to investigate the effect of 5-[2-dimethyl amino ethoxy] Indole 2,3-di one and 5-[2-dimethyl amino ethoxy] Indole 2-one,3-semicarbazone(IVa) derivatives on biogenic amines concentrations in rat brain after induction of seizures by Maximal Electro Shock(MES) method. Our aim of study was relationship between seizure activities and altered the monoamines such as noradrenaline (NA), dopamine (DA), serotonin (5-HT) in forebrain of rats in MES seizure models. In MES model, study of 5-[2-dimethyl amino ethoxy] Indole 2,3 dione(IIIa) and 5-[2-dimethyl amino ethoxy] Indole 2-one,3-semicarbazone(IVa) (100 mg/kg) showed significantly restored the decreased levels of brain monoamines such as Noradrenaline, Dopamine & 5-Hydroxy Triptamine. Thus, this study suggests that study of 5-[2-Dimethyl amino ethoxy] Indole 2,3-dione(IIIa) and 5-[2-dimethyl amino ethoxy] Indole 2-one,3-semicarbazone(IVa) increased the monoamines on rat brain, which may be decreased the susceptibility to MES induced seizure in rats.

In the present work, some new 5-Hydroxyindole 3-thiosemicarbazone 2-ones and 5-[2(3)-dialkylaminoalkoxy] Indole 3-hydrazone 2-ones were prepared from 5-hydroxy isatin. The structures of the products were characterized by IR, NMR, and MASS Spectral studies. All the compounds were examined for antioxidant activity by using 1,1-diphenyl-2-picryl-hydrazyl and hydrogen peroxide (H2O2), and the total antioxidant capacity by a phosphomolybdenum assay. In general, the derivatives were found to exhibit antioxidant activity. Further, the compounds with dialkyl amino alkoxy at the C5 position demonstrated significant antioxidant activity.

A simple, Accurate, precise method was developed for the simultaneous estimation of the Sofosbuvir and Ledipasvir in Tablet dosage form. Chromatogram was run through Std Discovery C8 150 x 4.6 mm, 5m. Mobile phase containing Buffer 0.1% OPA: Acetonitrile taken in the ratio 60:40 was pumped through column at a flow rate of 1 ml/min. Buffer used in this method was 0.1% OPA buffer. Temperature was maintained at 30°C. Optimized wavelength selected was 260 nm. Retention time of Sofosbuvir and Ledipasvir were found to be 2.367 min and 3.436 min. %RSD of the Sofosbuvir and Ledipasvir were and found to be 0.6 and 0.5 respectively. %Recovery was obtained as 99.61% and 99.80% for Sofosbuvir and Ledipasvir respectively. LOD, LOQ values obtained from regression equations of Sofosbuvir and Ledipasvir were 0.67, 2.02 and 0.70, 2.12 respectively. Regression equation of Sofosbuvir is y = 4266.x + 7700, and y = 4861.x + 2656.of Ledipasvir. Retention times were decreased and run time was decreased, so the method developed was simple and economical that can be adopted in regular Quality control test in Industries.

Finer understandings of drugs, for newly emerged diseases are becoming difficult nowadays. The contemporary approach is Drug Repurposing. Drug repurposing implies the exploration of surviving drugs for new restorative motive. Apart from conventional drug approaches, it is a profitable, brisk and reliable approach. The equivalent therapies for newly emerging and remerging viral infections are strenuous spot these days. The drug repurposing has helped in treating many viral reprofiling infectious diseases like CoVID-19, MERS, SARS, Influenza, Swine flu, Hanta, Zika, Ebola, Marburg, Human Adeno virus infection etc. The present review looks at describing the drug repurposing approach in various viral infections.